# EDGAR Filing Document

**Accession Number:** 0002094256
**File Stem:** 0001104659-26-070999
**Filing Date:** 2026-6
**Character Count:** 24463
**Document Hash:** 73e79afbae4ca8b74b97bf9d46af6eb6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-070999.hdr.sgml**: 20260605

**ACCESSION NUMBER**: 0001104659-26-070999

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 23

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260605

**DATE AS OF CHANGE**: 20260605

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BEACON TOPCO, INC.
- **CENTRAL INDEX KEY:** 0002094256
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-291359
- **FILM NUMBER:** 261069610

**BUSINESS ADDRESS:**
- **STREET 1:** 20400 CENTURY BOULEVARD, SUITE 210
- **CITY:** GERMANTOWN
- **STATE:** MD
- **ZIP:** 20874
- **BUSINESS PHONE:** 4439170966

**MAIL ADDRESS:**
- **STREET 1:** 20400 CENTURY BOULEVARD, SUITE 210
- **CITY:** GERMANTOWN
- **STATE:** MD
- **ZIP:** 20874

?xml version='1.0' encoding='ASCII'? Beacon Topco, Inc._March 31, 2026

[**Table of Contents**](#TOC)

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

☒**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended March 31, 2026**

**OR**

☐**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from&nbsp;&nbsp;&nbsp;&nbsp; to&nbsp;&nbsp;&nbsp;&nbsp;** 

**Commission File Number 333-291359**

**Beacon Topco, Inc.\***

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **41-2339925** |
| (State or other jurisdiction of | (I.R.S. Employer Identification No.) |
| incorporation or organization) |  |

---

---

| | |
|:---|:---|
| **20400 Century Boulevard, Suite 210Germantown, MD**<br>(Address of principal executive offices) | **20874**<br>(Zip Code) |

---

**(443) 917-0966**

**(Registrant's telephone number, including area code)**

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbols** | **Name of each exchange on which registered** |
| None | N/A | N/A |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Securities Exchange Act of 1934.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934). Yes ☒ No ☐

As of June 1, 2026, there were 100 outstanding shares of the registrant's common stock, $0.0001 par value per share.

**The registrant meets the conditions set forth in General Instructions (H)(1)(a) and (b) of Form 10-Q and therefore is filing this form with the reduced disclosure format permitted by Form 10-Q.**

\* The registrant is currently named Beacon Topco, Inc. The registrant plans to change its name to "Clywedog Therapeutics Holdings, Inc." following the completion of the transactions described herein.

------

[**Table of Contents**](#TOC)

#### **TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
|  |  | **Page** |
|  | [Explanatory Note](#EXPLANATORYNOTE_91961). | 3 |
|  | [**PART I - FINANCIAL INFORMATION**](#PARTIFINANCIALINFORMATION_202323) |  |
| [Item 1.](#Item1_220143) | [Financial Statements.](#FinancialStatements_41958) |  |
|  | [Consolidated Balance Sheets at March 31, 2026 and December 31, 2025](#CONSOLIDATEDBALANCESHEET_851081) | 4 |
|  | [Consolidated Statement of Operations for the three months ended March 31, 2026](#STATEMENTOFOPERATIONS_161321) | 5 |
|  | [Consolidated Statement of Comprehensive Income for the three months ended March 31, 2026](#COMPREHENSIVEINCOME_449152) | 6 |
|  | [Consolidated Statement of Cash Flows for the three months ended March 31, 2026](#CASHFLOWS_829433) | 7 |
|  | [Consolidated Statement of Equity for the three months ended March 31, 2026](#EQUITY_111990) | 8 |
|  | [Notes to Consolidated Financial Statements.](#NOTESTOCONSOLIDATED_634666) | 9 |
| [Item 2.](#Item2_118640) | [Management's Discussion and Analysis of Financial Condition and Results of Operations.](#ManagementsDiscussionandAnalysisofResult) | 10 |
| [Item 4.](#Item4_31259) | [Controls and Procedures.](#ControlsandProcedures_847959) | 11 |
|  | [**PART II - OTHER INFORMATION**](#PARTIIOTHERINFORMATION_30045) |  |
| [Item 1A.](#Item1A_650460) | [Risk Factors.](#RiskFactors_836182) | 11 |
| [Item 6.](#Item6_404671) | [Exhibits.](#Exhibits_192598) | 12 |

---

[**Table of Contents**](#TOC)

#### EXPLANATORY NOTE
Beacon Topco, Inc. (the "Company"), a Delaware corporation, was formed on September 24, 2025 for purposes of consummating the transactions described herein, and is a wholly-owned, direct subsidiary of Barinthus Biotherapeutics plc. On April 22, 2026, the United States Securities and Exchange Commission (the "SEC") declared effective the Registration Statement on Form S-4, as amended (the "Registration Statement"), of the Company. The Company has not commenced operations, has no assets or liabilities, and has not engaged in any significant activities other than those related to its formation from its incorporation on September 24, 2025 through March 31, 2026.

[**Table of Contents**](#TOC)

#### PART I - FINANCIAL INFORMATION

#### Item 1.&nbsp;&nbsp;&nbsp;&nbsp; Financial Statements.

#### BEACON TOPCO, INC. AND SUBSIDIARIES

#### CONSOLIDATED BALANCE SHEETS
**(In whole dollars)**

---

| | | |
|:---|:---|:---|
|  | **At**<br>**March 31, 2026** | **At**<br>**December 31, 2025** |
| **ASSETS**  |  |  |
| Current assets | $— | $— |
| Other assets |  |  |
| Total Assets | $— | $— |
| **LIABILITIES AND EQUITY**  |  |  |
| Current liabilities | $— | $— |
| Other liabilities |  |  |
| Commitments and contingencies |  |  |
| Equity: |  |  |
| &nbsp;&nbsp;Common Stock, par value $0.0001 per share; 100 shares authorized as of March 31, 2026 and December 31, 2025; 100 shares issued and outstanding as of March 31, 2026 and December 31, 2025 | 0<br><sup>1</sup> | 0<br><sup>1</sup> |
| &nbsp;&nbsp;Additional paid-in capital |  |  |
| &nbsp;&nbsp;Due from shareholder | (0)<br><sup>1</sup> | (0)<br><sup>1</sup> |
| &nbsp;&nbsp;Retained earnings  |  |  |
| &nbsp;&nbsp;Accumulated other comprehensive loss |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Equity |  |  |
| Total Liabilities and Equity | $— | $— |

---

<sup>1</sup>Indicates an amount less than 1

See notes to consolidated financial statements.

[**Table of Contents**](#TOC)

#### BEACON TOPCO, INC. AND SUBSIDIARIES

#### CONSOLIDATED STATEMENT OF OPERATIONS
**(In whole dollars)**

---

| | |
|:---|:---|
|  | **Three Months Ended** <br>**March 31, 2026** |
| Revenues  | $— |
| Operating expenses  |  |
| Other items |  |
| Earnings before income taxes |  |
| Provision for income taxes |  |
| Net earnings | $— |
| Earnings per share of common stock - basic and diluted | $— |
| Weighted average number of shares of common stock outstanding - basic and diluted | 100 |

---

See notes to consolidated financial statements.

[**Table of Contents**](#TOC)

#### BEACON TOPCO, INC. AND SUBSIDIARIES

#### CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
**(In whole dollars)**

---

| | |
|:---|:---|
|  | **Three Months Ended** <br>**March 31, 2026** |
| Net earnings | $— |
| &nbsp;&nbsp;Other comprehensive income before taxes |  |
| &nbsp;&nbsp;Provision for income taxes |  |
| Comprehensive income | $— |

---

See notes to consolidated financial statements.

[**Table of Contents**](#TOC)

#### BEACON TOPCO, INC. AND SUBSIDIARIES

#### CONSOLIDATED STATEMENT OF CASH FLOWS
**(In whole dollars)**

---

| | |
|:---|:---|
|  | **Three Months Ended** <br>**March 31, 2026** |
| **Operating Activities** |  |
| Net earnings  | $— |
| Adjustments to reconcile net earnings to net cash flow provided by operating activities:  |  |
| &nbsp;&nbsp;Change in assets and liabilities |  |
| Net cash flow provided by operating activities |  |
| **Investing Activities** |  |
| Net cash flow provided by investing activities |  |
| **Financing Activities** |  |
| Net cash flow provided by financing activities |  |
| Net increase in cash and cash equivalents |  |
| Cash and cash equivalents at beginning of year |  |
| Cash and cash equivalents at end of the period | $— |

---

See notes to consolidated financial statements.

[**Table of Contents**](#TOC)

#### BEACON TOPCO, INC. AND SUBSIDIARIES

#### CONSOLIDATED STATEMENT OF EQUITY
**(In whole dollars)**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | <br>**Common Stock** | <br>**Additional**<br>**Paid-In**<br>**Capital** | <br>**Treasury**<br>**Stock** | <br>**Due from**<br>**Shareholder** | <br>**Retained**<br>**Earnings** | **Accumulated**<br>**Other**<br> **Comprehensive**<br>**Loss** | <br>**Total Equity** |
|  | *(Shares)* |  |  |  |  |  |  |
| **December 31, 2025** | 100 | $0<br><sup>1</sup> | $— | $(0)<br><sup>1</sup> | $— | $— | $— |
| Net earnings |  |  |  |  |  |  |  |
| Stock issuance |  |  |  |  |  |  |  |
| **March 31, 2026** | 100 | $0<br><sup>1</sup> | $— | $(0)<br><sup>1</sup> | $— | $— | $— |

---

<sup>1</sup>Indicates an amount less than 1

See notes to consolidated financial statements.

[**Table of Contents**](#TOC)

#### BEACON TOPCO, INC. AND SUBSIDIARIES

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

#### 1) BASIS OF PRESENTATION
*Description of Business*

Beacon Topco, Inc., a Delaware corporation ("Topco" or the "Company"), was formed on September 24, 2025 as a wholly-owned, direct subsidiary of Barinthus Biotherapeutics plc, a public limited company organized under the laws of England and Wales ("Barinthus Bio"). The Company has one wholly-owned direct subsidiary, Cdog Merger Sub, Inc. ("Merger Sub"), which is a Delaware corporation. The Company has not commenced operations, has no assets or liabilities, and has not engaged in any significant activities other than those related to its formation from its incorporation on September 24, 2025 through March 31, 2026. The Company was formed for purposes of consummating a business combination (the "Transactions") with Barinthus Bio and Clywedog Therapeutics, Inc., a Delaware corporation ("Clywedog").

On September 29, 2025, the Company entered into an Agreement and Plan of Merger (the "Original Merger Agreement") with Barinthus Bio, Merger Sub, and Clywedog, as amended by that certain Amendment to the Original Merger Agreement, dated as of February 22, 2026 (such amendment, the "Merger Agreement Amendment" and, together with the Original Merger Agreement, as it may be further amended or modified from time to time, the "Merger Agreement"), pursuant to which (i) the Company will acquire all of the outstanding share capital of Barinthus Bio via a scheme of arrangement in accordance with Part 26 of the United Kingdom Companies Act 2006, and (ii) Merger Sub will merge with and into Clywedog, with Clywedog surviving as a wholly-owned subsidiary of the Company. Upon closing, Barinthus Bio shareholders are expected to own approximately 34% and Clywedog stockholders approximately 66% of the Company on a fully diluted basis, based on the respective capitalizations of Barinthus Bio and Clywedog as of the date the parties entered into the Merger Agreement. The Transactions have been unanimously approved by the boards of directors of each of Barinthus Bio and Clywedog.

At the closing of the Transactions, the shares of Topco common stock, par value $0.0001 per share, will be listed on the Nasdaq Stock Market under the ticker symbol "CLYD," and the Company will be renamed "Clywedog Therapeutics Holdings, Inc."

*Use of Estimates*

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the applicable periods presented. Actual results may vary from these estimates under different assumptions or conditions.

#### 2) EQUITY
At March 31, 2026, the Company was authorized to issue 100 shares of common stock, par value $0.0001 per share. At March 31, 2026, 100 shares of the Company's common stock were issued and outstanding. All such issued and outstanding shares were held by Barinthus Bio.

[**Table of Contents**](#TOC)

#### Item 2. &nbsp;&nbsp;&nbsp;&nbsp; Management's Discussion and Analysis of Financial Condition and Results of Operations.
We are a Delaware corporation formed on September 24, 2025 as a wholly-owned subsidiary of Barinthus Biotherapeutics plc ("Barinthus Bio") for purposes of consummating a business combination (the "Transactions") with Barinthus Bio and Clywedog Therapeutics, Inc., a Delaware corporation ("Clywedog"). We have one wholly-owned direct subsidiary, Cdog Merger Sub, Inc. ("Merger Sub"), which is a Delaware corporation. We have not commenced operations and have not engaged in any significant activities other than those related to our formation from our incorporation on September 24, 2025 through March 31, 2026.

On September 29, 2025, we entered into an Agreement and Plan of Merger (the "Original Merger Agreement") with Barinthus Bio, Merger Sub, and Clywedog, as amended by that certain Amendment to the Original Merger Agreement, dated as of February 22, 2026 (such amendment, the "Merger Agreement Amendment" and, together with the Original Merger Agreement, as it may be further amended or modified from time to time, the "Merger Agreement"), pursuant to which (i) we will acquire all of the outstanding share capital of Barinthus Bio via a scheme of arrangement in accordance with Part 26 of the United Kingdom Companies Act 2006, and (ii) Merger Sub will merge with and into Clywedog, with Clywedog surviving as our wholly-owned subsidiary. Upon closing, Barinthus Bio shareholders are expected to own approximately 34% and Clywedog stockholders approximately 66% of our outstanding capital stock on a fully diluted basis, based on the respective capitalizations of Barinthus Bio and Clywedog as of the date the parties entered into the Merger Agreement. The Transactions have been unanimously approved by the boards of directors of each of Barinthus Bio and Clywedog.

On April 22, 2026, the United States Securities and Exchange Commission (the "SEC") declared effective our Registration Statement on Form S-4, as amended, to register shares of our common stock, par value $0.0001 per share, that will be issued in connection with the Transactions.

At the closing of the Transactions, our shares of common stock will be listed on the Nasdaq Stock Market under the ticker symbol "CLYD," and we will be renamed "Clywedog Therapeutics Holdings, Inc."

[**Table of Contents**](#TOC)

#### Item 4. &nbsp;&nbsp;&nbsp;&nbsp; Controls and Procedures.
Our principal executive officer and principal financial officer has concluded that, as of the end of the period covered by this report, our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) were effective, based on the evaluation of these controls and procedures required by Rule 13a-15(b) or 15d-15(b) of the Exchange Act.

There have been no changes in our internal control over financial reporting during the current fiscal quarter that have materially affected, or are reasonably likely to materially affect, the effectiveness of such controls.

#### PART II - OTHER INFORMATION

#### Item 1A.&nbsp;&nbsp;&nbsp;&nbsp; Risk Factors.
During the period covered by this report, we did not conduct any significant activities other than those related to its formation and the matters contemplated by the Transactions. See "Cautionary Statement Regarding Forward Looking Statements" and "Risk Factors" in our Registration Statement on Form S-4 (File No. 333-291359) filed with and declared effective by the SEC on April 22, 2026, which is incorporated by reference herein.

[**Table of Contents**](#TOC)

#### Item 6.&nbsp;&nbsp;&nbsp;&nbsp; Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description of Document** |
| 31.1\* | [Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](tmb-20260331xex31d1.htm) |
| 32.1\*\* | [Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](tmb-20260331xex32d1.htm) |
| 101.INS\* | Inline XBRL Instance Document. |
| 101.SCH\* | Inline XBRL Taxonomy Extension Schema Document. |
| 101.CAL\* | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.DEF\* | Inline XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB\* | Inline XBRL Taxonomy Extension Label Linkbase Document. |
| 101.PRE\* | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
| 104\* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |

---

**\***Filed herewith.

\*\* This certification will not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.

[**Table of Contents**](#TOC)

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **BEACON TOPCO, INC.** | **BEACON TOPCO, INC.** |
| Date: June 5, 2026 | By:  | /s/ William Enright |
|  |  | William Enright |
|  |  | Chief Executive Officer |
|  |  | (Principal Executive Officer and Principal Financial Officer) |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION PURSUANT TO**

**RULES 13a-14**(**a**) **AND 15d-14**(**a**) **UNDER THE SECURITIES EXCHANGE ACT OF 1934**,

**AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, William Enright, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this Quarterly Report on Form 10-Q of Beacon Topco, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) (Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: June 5, 2026 | /s/ William Enright |
|  | Name: William Enright |
|  | Title: Chief Executive Officer<br>(Principal Executive Officer and Principal Financial Officer) |

---

------

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATIONS PURSUANT TO**

**18U**.**S**.**C**. **SECTION 1350**, **AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Beacon Topco, Inc. (the "Company") on Form 10-Q for the period ending March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

---

| | |
|:---|:---|
| Date: June 5, 2026<br>| /s/ William Enright<br>|
|  | Name: William Enright<br>|
|  | Title: Chief Executive Officer<br>|
|  | (Principal Executive Officer and Principal Financial Officer)<br>|

---

------